LON:SHP - Shire Stock Price, News, & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Sign in or create an account to add this stock to your watchlist.
Previous CloseGBX 4,690
Today's RangeGBX 4,690 - GBX 4,690
52-Week RangeGBX 2,940.50 - GBX 5,021
VolumeN/A
Average Volume3.14 million shs
Market Capitalization£42.73 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc., as well as a preclinical research collaboration agreement with NanoMedSyn. The company was founded in 1986 and is headquartered in Dublin, Ireland.

Receive SHP News and Ratings via Email

Sign-up to receive the latest news and ratings for SHP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+353-1-6096000

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap£42.73 billion
Next Earnings DateN/A
OptionableNot Optionable

Shire (LON:SHP) Frequently Asked Questions

What is Shire's stock symbol?

Shire trades on the London Stock Exchange (LON) under the ticker symbol "SHP."

How often does Shire pay dividends? What is the dividend yield for Shire?

Shire declared a dividend on Tuesday, July 31st. Stockholders of record on Thursday, September 6th will be paid a dividend of GBX 4.26 per share on Friday, October 19th. This represents a dividend yield of 0.1%. The ex-dividend date is Thursday, September 6th. The official announcement can be seen at this link. View Shire's Dividend History.

What price target have analysts set for SHP?

19 equities research analysts have issued twelve-month price targets for Shire's shares. Their forecasts range from GBX 3,600 to GBX 7,500. On average, they anticipate Shire's stock price to reach GBX 4,608 in the next year. View Analyst Price Targets for Shire.

What is the consensus analysts' recommendation for Shire?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Shire in the last year. There are currently 6 hold ratings, 12 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Shire.

Has Shire been receiving favorable news coverage?

News coverage about SHP stock has trended somewhat positive on Monday, InfoTrie Sentiment reports. The research firm identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Shire earned a news sentiment score of 1.4 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are some of Shire's key competitors?

What other stocks do shareholders of Shire own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Shire investors own include Barclays (BARC), Centrica (CNA), GlaxoSmithKline (GSK), Lloyds Banking Group (LLOY), Prudential (PRU), Rio Tinto (RIO), Vodafone Group (VOD), Endologix (ELGX), Shire (SHPG) and AstraZeneca (AZN).

Who are Shire's key executives?

Shire's management team includes the folowing people:
  • Dr. Flemming Ornskov M.P.H., MBA, M.D., MPH, CEO, MD & Exec. Director (Age 60)
  • Mr. Thomas J. W. Dittrich, CFO & Director (Age 54)
  • Gisele Dion, Chief Accounting Officer
  • Mr. Matthew Walker, Head of Technical Operations (Age 54)
  • Dr. Andreas Busch Ph.D., Head of R&D and Chief Scientific Officer (Age 55)

How big of a company is Shire?

Shire has a market capitalization of £0.00.

What is Shire's official website?

The official website for Shire is http://www.shire.com/.

How can I contact Shire?

Shire's mailing address is Miesian Plaza 50-58 Baggot Street Lower, Block 2, DUBLIN, D02 HW68, Ireland. The biopharmaceutical company can be reached via phone at +353-1-6096000.


MarketBeat Community Rating for Shire (LON SHP)

Community Ranking:  4.0 out of 5 (star star star star)
Outperform Votes:  1,438 (Vote Outperform)
Underperform Votes:  360 (Vote Underperform)
Total Votes:  1,798
MarketBeat's community ratings are surveys of what our community members think about Shire and other stocks. Vote "Outperform" if you believe SHP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SHP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel